AbbVie Inc. is 38.5x more valuable than Summit Therapeutics Inc. by market capitalization ($397.44 B vs $10.33 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SMMT | ABBV |
|---|---|---|
| Market cap | $10.33 B | $397.44 B |
| US-listed rank | #923 | #28 |
| Revenue (latest FY) | $0.00 | $61.16B |
| Net income (latest FY) | -$1.08B | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 532 | 1,008 |
AbbVie Inc. is 38.5x more valuable than Summit Therapeutics Inc. by market capitalization ($397.44 B vs $10.33 B).
In their latest fiscal years, Summit Therapeutics Inc. reported $0.00 in revenue while AbbVie Inc. reported $61.16B.
Full pages: Summit Therapeutics Inc. and AbbVie Inc., or browse the full rankings.